Drug name - Qtern

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(9 months from now)

US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(2 years from now)

US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(7 years from now)

CN1896088A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Jul, 2009

(13 years ago)

CN1698601A ASTRAZENECA AB Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof
Mar, 2010

(12 years ago)

CN101092409A ASTRAZENECA AB C-Glucosinolates Sglt2 Inhibitor And Method
May, 2011

(11 years ago)

CN1284793C ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

CN1407990A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

CN1213028C ASTRAZENECA AB Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof
Mar, 2021

(1 year, 7 months ago)

CN1427826A ASTRAZENECA AB Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof
Mar, 2021

(1 year, 7 months ago)

CN1653075A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN102627676A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitor And Method
May, 2023

(7 months from now)

CN101628905A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN102627676B ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitor And Method
May, 2023

(7 months from now)

CN101628905B ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN100534997C ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN101479287B ASTRAZENECA AB Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

CN103319445A ASTRAZENECA AB Sglt2 Inhibitor Crystal Structure And Its Preparation Method
Jun, 2027

(4 years from now)

CN101479287A ASTRAZENECA AB Crystalline Solvates And Complexes Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl)Methyl)Phenyl)-D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

CN103145773B ASTRAZENECA AB Used As Sglt2 Inhibitors For The Treatment Of Diabetes, (1S) -1, 5 - -L-C-(3 - ((Phenyl) Methyl) Phenyl) Crystalline Solvates And Complexes Of -D - Glucitol Derivatives And Amino Acid
Jun, 2027

(4 years from now)

CN103145773A ASTRAZENECA AB Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

CN103319445B ASTRAZENECA AB Crystal Structure Of The Sglt2 Inhibitor And Preparation Method Thereof
Jun, 2027

(4 years from now)

IN200200433P3 ASTRAZENECA AB A C-Aryl Glucoside
Oct, 2020

(2 years ago)

IN200201154P3 ASTRAZENECA AB A Cyclopropyl-Fused Pyrrolidine-Based Compound
Mar, 2021

(1 year, 7 months ago)

IN206543B ASTRAZENECA AB A Cyclopropyl-Fused Pyrrolidine-Based Compound
Mar, 2021

(1 year, 7 months ago)

IN200700019I3 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
Jan, 2027

(4 years from now)

EP1224195A1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

EP1224195B1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

EP1559710A3 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Process For Their Preparation And Their Use
Mar, 2021

(1 year, 7 months ago)

EP2995615B1 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv And Their Pharmaceutical Use
Mar, 2021

(1 year, 7 months ago)

EP1559710B1 ASTRAZENECA AB Dipeptidyl Peptidase Iv Inhibitors Based On Cyclopropyl-Fused Pyrrolidine, Process For Their Preparation And Their Use
Mar, 2021

(1 year, 7 months ago)

EP2272825A2 ASTRAZENECA AB Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation
Mar, 2021

(1 year, 7 months ago)

EP2995615A1 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv And Their Pharmaceutical Use
Mar, 2021

(1 year, 7 months ago)

EP2272825A3 ASTRAZENECA AB N-Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation
Mar, 2021

(1 year, 7 months ago)

EP2272825B1 ASTRAZENECA AB Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation
Mar, 2021

(1 year, 7 months ago)

EP1559710A2 ASTRAZENECA AB Dipeptidyl Peptidase Iv Inhibitors Based On Cyclopropyl-Fused Pyrrolidine, Process For Their Preparation And Their Use
Mar, 2021

(1 year, 7 months ago)

EP1261586B1 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Processes For Their Preparation, And Their Use
Mar, 2026

(3 years from now)

EP1261586A2 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Processes For Their Preparation, And Their Use
Mar, 2026

(3 years from now)

EP2069374B1 ASTRAZENECA AB Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP2069374A1 ASTRAZENECA AB Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP3363807A1 ASTRAZENECA AB Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate
Jun, 2027

(4 years from now)

EP3045466A1 ASTRAZENECA AB (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP2069374B2 ASTRAZENECA AB Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP3045466B1 ASTRAZENECA AB (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP3363807B1 ASTRAZENECA AB Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate
Jun, 2027

(4 years from now)

EP1506211A4 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

EP1506211B1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

EP1506211A1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8628799 ASTRAZENECA AB Coated tablet formulation and method Jul, 2025

(2 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same Jun, 2027

(4 years from now)

US8221786 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Mar, 2028

(5 years from now)

US8716251 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Mar, 2028

(5 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Mar, 2028

(5 years from now)

Drugs and Companies using DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE ingredient

Treatment: Treatment of type 2 diabetes mellitus; method for treating type 2 diabetes mellitus (t2dm) in patients who have inadequate control with dapagliflozin; method for treating type 2 diabetes mellitus (t2dm) in patients who are already treated with dapagliflozin and saxagliptin; Treatment of type 2 diabetes mellitus; method for treating type 2 diabetes mellitus (t2dm) in patients who are already treated with dapagliflozin and saxagliptin; method for treating type 2 diabetes mellitus (t2dm) in patients who have inadequate control with dapagliflozin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG;EQ 5MG BASE TABLET;ORAL Prescription
10MG;EQ 5MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.